Holen Sie sich die Stockscreener-App
4.814
5.87%
-0.296
Überblick
Nachrichten
Preisverlauf
Optionskette
Financials
Warum fällt ACHV?
Forum
Prognose
Aktiensplit
Schlusskurs vom Vortag:
$5.11
Offen:
$5.07
24-Stunden-Volumen:
612.49K
Relative Volume:
0.43
Marktkapitalisierung:
$245.81M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-32.94M
KGV:
-4.3369
EPS:
-1.11
Netto-Cashflow:
$-24.95M
1W Leistung:
+0.63%
1M Leistung:
+52.70%
6M Leistung:
+87.16%
1J Leistung:
+1.48%
1-Tages-Spanne:
$4.775
$5.145
1-Wochen-Bereich:
$4.70
$5.42
52-Wochen-Spanne:
$1.84
$5.78
Achieve Life Sciences Inc Stock (ACHV) Company Profile
Firmenname
Achieve Life Sciences Inc
Sektor
Branche
Telefon
425-686-1500
Adresse
22722 29TH DR. SE, SEATTLE, BC
Vergleichen Sie ACHV mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
ACHV
Achieve Life Sciences Inc
|
4.81 | 261.15M | 0 | -32.94M | -24.95M | -1.11 |
|
VRTX
Vertex Pharmaceuticals Inc
|
425.22 | 109.22B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
629.22 | 67.50B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
423.73 | 57.35B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
837.59 | 50.87B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
183.82 | 39.72B | 447.02M | -1.18B | -868.57M | -6.1812 |
Achieve Life Sciences Inc Stock (ACHV) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-08-21 | Eingeleitet | H.C. Wainwright | Buy |
| 2024-11-14 | Eingeleitet | Rodman & Renshaw | Buy |
| 2024-09-27 | Eingeleitet | Raymond James | Strong Buy |
| 2023-05-10 | Bestätigt | Maxim Group | Buy |
| 2021-06-23 | Eingeleitet | Oppenheimer | Outperform |
Achieve Life Sciences Inc Aktie (ACHV) Neueste Nachrichten
Achieve Life Sciences Inc expected to post a loss of 26 cents a shareEarnings Preview - TradingView
Why Achieve Life Sciences Inc. stock could rally in 20252025 Major Catalysts & Accurate Technical Buy Alerts - newser.com
Is Achieve Life Sciences Inc. (SP4P) stock a defensive play amid uncertainty2025 Geopolitical Influence & AI Forecast for Swing Trade Picks - newser.com
Can Achieve Life Sciences Inc. (SP4P) stock sustain institutional flowsJuly 2025 Highlights & AI Driven Price Predictions - newser.com
Ranking Achieve Life Sciences Inc. among high performing stocks via toolsEarnings Risk Summary & Short-Term Trading Alerts - newser.com
Is Achieve Life Sciences Inc. (SP4P) stock supported by strong fundamentalsJuly 2025 Selloffs & Short-Term High Return Ideas - newser.com
Why Achieve Life Sciences Inc. (SP4P) stock could outperform next yearEarnings Summary Report & Verified High Yield Trade Plans - newser.com
Is Achieve Life Sciences Inc. stock near bottom after declineJuly 2025 Gainers & Weekly High Conviction Trade Ideas - newser.com
What dividend safety score for Achieve Life Sciences Inc. stockJuly 2025 Decliners & Fast Exit Strategy with Risk Control - newser.com
Is Achieve Life Sciences Inc. stock supported by strong cash flowsStop Loss & AI Driven Price Forecasts - newser.com
What insider trading reveals about Achieve Life Sciences Inc. stock2025 Trading Volume Trends & Weekly High Conviction Trade Ideas - newser.com
Achieve Life Sciences completes key milestones for smoking cessation drug By Investing.com - Investing.com Nigeria
Achieve Life Sciences (ACHV) Reports Key Updates in Cytisinicline Safety Trial - GuruFocus
Achieve Life Sciences completes key milestones for smoking cessation drug - Investing.com
Achieve Life Sciences Announces Positive Outcomes from ORCA-OL Trial and Submits 120-Day Safety Update to FDA for Cytisinicline - Quiver Quantitative
Achieve Life Sciences Meets Key Milestones Advancing Cytisinicline NDA for Smoking Cessation - The Manila Times
Achieve (NASDAQ: ACHV) completes ORCA-OL; 334 one-year participants exceed FDA request - Stock Titan
When is the best time to exit Achieve Life Sciences Inc.Earnings Recap Report & Smart Money Movement Tracker - newser.com
Is Achieve Life Sciences Inc. still worth holding after the dipJuly 2025 Weekly Recap & Verified Momentum Stock Ideas - newser.com
Can Achieve Life Sciences Inc. (SP4P) stock sustain breakout momentumQuarterly Portfolio Summary & Weekly High Potential Alerts - newser.com
Can Achieve Life Sciences Inc. stock withstand economic slowdownQuarterly Market Summary & Verified Momentum Stock Alerts - newser.com
How to recover losses in Achieve Life Sciences Inc. stockPortfolio Risk Summary & Risk Controlled Daily Trade Plans - newser.com
Real time pattern detection on Achieve Life Sciences Inc. stockWeekly Trend Report & Low Risk High Win Rate Stock Picks - newser.com
Can Achieve Life Sciences Inc. (SP4P) stock retain market dominanceQuarterly Earnings Summary & Community Consensus Stock Picks - newser.com
Will Achieve Life Sciences Inc. stock continue dividend increasesJuly 2025 Final Week & Weekly Top Performers Watchlists - newser.com
Achieve Life Sciences Inc. stock momentum explained2025 Price Action Summary & Community Driven Trade Alerts - newser.com
Will Achieve Life Sciences Inc. (SP4P) stock benefit from commodity supercycleJuly 2025 Final Week & Safe Entry Trade Signal Reports - newser.com
Advanced analytics toolkit walkthrough for Achieve Life Sciences Inc.Wall Street Watch & Expert Curated Trade Setups - newser.com
Can Achieve Life Sciences Inc. stock deliver strong Q4 earningsJuly 2025 Highlights & Entry Point Confirmation Signals - newser.com
Is Achieve Life Sciences Inc. (SP4P) stock a momentum leader2025 Biggest Moves & Daily Risk Controlled Trade Plans - newser.com
How Achieve Life Sciences Inc. (SP4P) stock reacts to monetary easing2025 Big Picture & Real-Time Volume Surge Alerts - newser.com
Will Achieve Life Sciences Inc. stock deliver long term returnsEarnings Overview Summary & Real-Time Market Sentiment Reports - newser.com
Finanzdaten der Achieve Life Sciences Inc-Aktie (ACHV)
Umsatz
Nettogewinn
Free Cashflow
ENV
1.19%
0.47%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):